SCHEMBL298430

SCHEMBL298430

CNC=O.Cc1ccc(N)c(C(=O)O)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.50
KMT2A Q03164 5/20 0.50
MAPT P10636 3/20 0.50
ALDH1A1 P00352 3/20 0.50
GFER P55789 2/20 0.50
NPC1 O15118 2/20 0.50
CDC25B P30305 1/20 0.50
CASP6 P55212 1/20 0.50
RCE1 Q9Y256 1/20 0.50
MAPK1 P28482 1/20 0.50
HTT P42858 1/20 0.50
RXFP1 Q9HBX9 1/20 0.50
MEN1 O00255 4/20 0.49
TDP1 Q9NUW8 3/20 0.49
THRB P10828 2/20 0.49
USP2 O75604 1/20 0.49
POLB P06746 1/20 0.49
PKM P14618 1/20 0.49
APEX1 P27695 1/20 0.49
RECQL P46063 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31022638 0.88 KMT2A (0.63) KDM4EKMT2AMAPTALDH1A1GFER
SCHEMBL221528 0.88 KMT2A (0.63) KDM4EKMT2AMAPTALDH1A1GFER
SCHEMBL10800691 0.86 KMT2A (0.61) KDM4EKMT2AMAPTALDH1A1GFER
Nitrogen SCHEMBL28647368 0.84 KMT2A (0.59) KDM4EKMT2AMAPTALDH1A1GFER
SCHEMBL297338 0.84 ALDH1A1 (0.58) KDM4EMAPTALDH1A1NPC1MAPK1
SCHEMBL1322668 0.76 MAPT (0.43) KDM4EKMT2AMAPTALDH1A1GFER
SCHEMBL1558074 0.75 MAPT (0.56) KDM4EMAPTALDH1A1NPC1MAPK1
SCHEMBL295645 0.75 DTYMK (0.51) KDM4EKMT2AMAPTALDH1A1MEN1
SCHEMBL29017626 0.74 KDM4E (0.53) KDM4EKMT2AMAPTALDH1A1GFER
SCHEMBL5383825 0.74 MAPT (0.73) MAPTNPC1MAPK1HTTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546610-B2 Method for preparing phenylalanine derivatives having quinazoline-dione skeleton and intermediates for use in the preparation of the derivatives AJINOMOTO CO., INC. (JP) 2013-10-01 US disclosed
EP-2103601-B1 PROCESS FOR PRODUCTION OF PHENYLALANINE DERIVATIVES HAVING QUINAZOLINEDIONE SKELETONS AND INTERMEDIATES FOR THE PRODUCTION AJINOMOTO KK (JP) 2012-03-14 EP disclosed
US-20110313154-A1 METHOD FOR PREPARING PHENYLALANINE DERIVATIVES HAVING QUINAZOLINE-DIONE SKELETON AND INTERMEDIATES FOR USE IN THE PREPARATION OF THE DERIVATIVES AJINOMOTO CO., INC. (JP) 2011-12-22 US disclosed
US-8058432-B2 Method for preparing phenylalanine derivatives having quinazoline-dione skeleton and intermediates for use in the preparation of derivatives AJINOMOTO CO., INC. (JP) 2011-11-15 US disclosed
US-20090318688-A1 METHOD FOR PREPARING PHENYLALANINE DERIVATIVES HAVING QUINAZOLINE-DIONE SKELETON AND INTERMEDIATES FOR USE IN THE PREPARATION OF DERIVATIVES AJINOMOTO CO., INC. (JP) 2009-12-24 US disclosed
EP-2103601-A1 PROCESS FOR PRODUCTION OF PHENYLALANINE DERIVATIVES HAVING QUINAZOLINEDIONE SKELETONS AND INTERMEDIATES FOR THE PRODUCTION Ajinomoto Co., Inc. (JP) 2009-09-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318688-A1 METHOD FOR PREPARING PHENYLALANINE DERIVATIVES HAVING QUINAZOLINE-DIONE SKELETON AND INTERMEDIATES FOR USE IN THE PREPARATION OF DERIVATIVES PAH, DDC, AADAT KDM4E 979/4885KMT2A 759/4885MAPT 3960/4885
US-20110313154-A1 METHOD FOR PREPARING PHENYLALANINE DERIVATIVES HAVING QUINAZOLINE-DIONE SKELETON AND INTERMEDIATES FOR USE IN THE PREPARATION OF THE DERIVATIVES PAH, DDC, ASNS KDM4E 1138/4885KMT2A 945/4885MAPT 4025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.